AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Inc. to discuss Q4/FY2023 results in a conference call on April 2, 2024, led by CEO Thomas K. Equels and Scientific Officer Christopher McAleer.
03/26/2024 - 09:05 AM
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.
The call will be hosted by members of AIM’s leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com , and will be archived for 90 days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .
When will AIM ImmunoTech Inc. host a conference call to discuss Q4/FY2023 results?
AIM ImmunoTech Inc. will host a conference call on April 2, 2024, at 8:30 AM ET.
Who will lead the conference call for AIM ImmunoTech Inc.?
The conference call will be led by Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer.
How can participants access the conference call?
Interested participants can dial (877) 407-9219 (domestic) or (201) 689-8852 (international) and reference the AIM ImmunoTech Conference Call.
Where can the webcast of the conference call be accessed?
The webcast will be available on the Events page of the Investors section of AIM ImmunoTech Inc.'s website, aimimmuno.com, and will be archived for 90 days.
AIM Rankings
#3581 Ranked by Stock Gains
AIM Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Ocala
About AIM
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
